Skip to content
Case report

[Thiotepa-busulfan-fludarabine conditioning in allogeneic hematopoietic stem cell transplantation for blast-phase myeloproliferative neoplasm].

2026 · [Rinsho ketsueki] The Japanese journal of clinical hematology · Vol 67 8, pp. 934-939 · 0 citations
Medicine

TL;DR

This case suggests that a multidisciplinary treatment strategy incorporating TBF conditioning may improve relapse-free survival in patients with BP-MPN.

View source

Similar papers

Open access Aug 2026

Allogeneic stem cell transplantation after myeloablative conditioning with fludarabine, thiotepa, and cyclophosphamide in relapsed or refractory aggressive B-cell and T-cell lymphomas: results of the prospective ASTRAL study.

The data suggest that alloSCT can be effective after CART failure, with more than one-third of patients being in remission after two years, and these findings support the continued use of alloSCT in patients with aggressive lymphomas.

A. O. Saidy, B. Altmann, P. van Heteren et al. · 0 citations
Aug 2026

Feasibility of 8 Gy TBI-Busulfan-Fludarabine Conditioning with Post-Transplant Cyclophosphamide for Pediatric High-Risk or Relapsed Acute Lymphoblastic Leukemia.

8 Gy TBI-Bu-Flu with PTCy is a feasible reduced-radiation conditioning platform, providing reliable engraftment and encouraging leukemia control with no NRM in pediatric high-risk or relapsed ALL, however, the GVHD incidence was higher than anticipated, indicating that the prophylaxis backbone should be optimized in fu...

J. Yoo, Suejung Jo, Seongkoo Kim et al. · 0 citations
Review 2026

[Prophylactic or pre-emptive therapy with azacitidine or FLT3 inhibitor after allogeneic hematopoietic stem cell transplantation for AML and MDS].

A review of the current concepts of post-transplant maintenance therapy in AML/MDS discusses emerging evidence supporting MRD-guided treatment strategies and molecularly targeted maintenance approaches, highlighting future perspectives for optimizing relapse prevention after allo-HSCT.

Y. Najima · 0 citations
Open access Oct 2026

CD25-based graft-versus-host disease prophylaxis after haploidentical hematopoietic stem cell transplantation: comparison of two prophylactic strategies.

It is suggested that a higher-dose anti-CD25, methotrexate-free prophylactic approach may reduce acute GVHD and improve GRFS after haplo-HSCT, while its effects on long-term disease control and survival require confirmation in multicenter randomized trials.

Qian-Lin Liu, Ao Zhang, Hong-Ru Chen et al. · 0 citations
Open access Aug 2026

Mitigating HLA Disparity in AML Transplantation: Comparable Outcomes After Haploidentical and 9/10 Mismatched Unrelated Donor Transplantation With Treosulfan and PTCy

It is suggested that, within a treosulfan–PTCy platform, major transplant outcomes are comparable between donor types, although haploidentical transplantation was associated with a higher incidence of chronic GVHD.

D. Avenoso, M. Farina, M. Malagola et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.